QIAGEN has secured a new contract from the US Government to boost production capacity for Covid-19 tests running on NeuMoDx instruments. The $3.4m contract was awarded by the Department of Defense (DoD). Under the contract, QIAGEN will increase production of PCR tests for NeuMoDx 96 and 288 clinical integrated systems at its site in Michigan. The company aims to ramp up production by the end of March 2022 from 10 million tests a year to more than 16 million.
Longhorn Vaccines & Diagnostics and SiO2 Materials Science have entered into a partnership to deliver FDA-cleared sample collection system PrimeStore MTM in 12mm sample transport tubes. The SiO2-manufactured sample transport tubes are available for testing Covid-19, influenza and other viruses. The use of transport tubes will enable large laboratories to pool ten times more samples with one-tenth of the required materials, the partners said. The combination will also allow labs to use one tube to test multiple viruses.
Curebase has supported InBios International in gaining Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its SCoV-2 Detect IgG Rapid Test. Curebase ran a decentralised clinical trial of the antibody test to procure necessary data for FDA requirements. In a clinical evaluation, InBios’s SCoV-2 Detect IgG Rapid Test determined 96.9% (PPA) of those who were positive and 100% of those who were negative (NPA) for SARS-CoV-2 (COVID-19) IgG antibodies. The test is designed to identify individuals who have an adaptive immune response to SARS-CoV-2.